JCR Pharmaceuticals Co., Ltd. (4552.T)
JPY 610.0
(-0.81%)
JPY 610.0
(-0.81%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 7.53 Billion JPY | 51.4% |
| 2022 | 4.97 Billion JPY | -75.04% |
| 2021 | 19.93 Billion JPY | 141.06% |
| 2020 | 8.26 Billion JPY | 154.9% |
| 2019 | 3.24 Billion JPY | -34.69% |
| 2018 | 4.96 Billion JPY | 31.26% |
| 2017 | 3.78 Billion JPY | 60.2% |
| 2016 | 2.36 Billion JPY | 9.72% |
| 2015 | 2.15 Billion JPY | 6.86% |
| 2014 | 2.01 Billion JPY | 30.36% |
| 2013 | 1.54 Billion JPY | 34.28% |
| 2012 | 1.15 Billion JPY | 5.61% |
| 2011 | 1.08 Billion JPY | -22.58% |
| 2010 | 1.4 Billion JPY | -29.89% |
| 2009 | 2 Billion JPY | 267.38% |
| 2008 | 546.47 Million JPY | 93.81% |
| 2007 | 281.96 Million JPY | 272.38% |
| 2006 | -163.57 Million JPY | -362.5% |
| 2005 | -35.36 Million JPY | -107.7% |
| 2004 | 459.5 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -443 Million JPY | 133.88% |
| 2024 Q1 | -510 Million JPY | 9290.91% |
| 2023 Q3 | 911 Million JPY | -81.15% |
| 2023 Q4 | -277 Million JPY | -130.41% |
| 2023 FY | 7.53 Billion JPY | 51.4% |
| 2023 Q1 | 2.06 Billion JPY | 9290.91% |
| 2023 Q2 | 4.83 Billion JPY | 133.88% |
| 2022 Q4 | 22 Million JPY | -99.48% |
| 2022 FY | 4.97 Billion JPY | -75.04% |
| 2022 Q1 | 1.53 Billion JPY | -2.6% |
| 2022 Q2 | -792 Million JPY | -151.56% |
| 2022 Q3 | 4.2 Billion JPY | 631.44% |
| 2021 Q4 | 1.57 Billion JPY | -66.56% |
| 2021 Q3 | 4.71 Billion JPY | -55.74% |
| 2021 FY | 19.93 Billion JPY | 141.06% |
| 2021 Q1 | 2.98 Billion JPY | -30.88% |
| 2021 Q2 | 10.65 Billion JPY | 257.1% |
| 2020 Q3 | 2.64 Billion JPY | 405.74% |
| 2020 Q4 | 4.31 Billion JPY | 63.21% |
| 2020 FY | 8.26 Billion JPY | 154.9% |
| 2020 Q1 | 784 Million JPY | -28.21% |
| 2020 Q2 | 523 Million JPY | -33.29% |
| 2019 Q3 | 1.15 Billion JPY | 114.9% |
| 2019 Q2 | 537 Million JPY | 16.49% |
| 2019 Q1 | 461 Million JPY | -81.15% |
| 2019 FY | 3.24 Billion JPY | -34.69% |
| 2019 Q4 | 1.09 Billion JPY | -5.37% |
| 2018 FY | 4.96 Billion JPY | 31.26% |
| 2018 Q2 | 1.4 Billion JPY | 160.85% |
| 2018 Q3 | 577 Million JPY | -58.96% |
| 2018 Q4 | 2.44 Billion JPY | 323.74% |
| 2018 Q1 | 539 Million JPY | 11.83% |
| 2017 Q2 | 1.83 Billion JPY | 201.81% |
| 2017 FY | 3.78 Billion JPY | 60.2% |
| 2017 Q4 | 482 Million JPY | -43.63% |
| 2017 Q3 | 855 Million JPY | -53.48% |
| 2017 Q1 | 609 Million JPY | 20.96% |
| 2016 Q2 | 1 Billion JPY | 178.65% |
| 2016 Q1 | 362.03 Million JPY | 61.27% |
| 2016 FY | 2.36 Billion JPY | 9.72% |
| 2016 Q4 | 503.48 Million JPY | 3.24% |
| 2016 Q3 | 487.69 Million JPY | -51.66% |
| 2015 Q1 | 455.24 Million JPY | -45.03% |
| 2015 Q4 | 224.48 Million JPY | -65.74% |
| 2015 FY | 2.15 Billion JPY | 6.86% |
| 2015 Q3 | 655.17 Million JPY | -19.89% |
| 2015 Q2 | 817.86 Million JPY | 79.65% |
| 2014 FY | 2.01 Billion JPY | 30.36% |
| 2014 Q2 | 232.52 Million JPY | 9.36% |
| 2014 Q3 | 741.29 Million JPY | 218.81% |
| 2014 Q4 | 828.16 Million JPY | 11.72% |
| 2014 Q1 | 212.61 Million JPY | 26.95% |
| 2013 Q3 | 710.19 Million JPY | 134.56% |
| 2013 Q4 | 167.48 Million JPY | -76.42% |
| 2013 Q2 | 302.78 Million JPY | -17.05% |
| 2013 Q1 | 365 Million JPY | -14.73% |
| 2013 FY | 1.54 Billion JPY | 34.28% |
| 2012 Q2 | 277.96 Million JPY | 123.46% |
| 2012 Q4 | 428.04 Million JPY | 13.37% |
| 2012 FY | 1.15 Billion JPY | 5.61% |
| 2012 Q1 | 124.39 Million JPY | 30.73% |
| 2012 Q3 | 377.57 Million JPY | 35.83% |
| 2011 Q3 | 415.12 Million JPY | 4.18% |
| 2011 Q2 | 398.47 Million JPY | 158.4% |
| 2011 Q1 | 154.2 Million JPY | 407.67% |
| 2011 FY | 1.08 Billion JPY | -22.58% |
| 2011 Q4 | 95.15 Million JPY | -77.08% |
| 2010 Q1 | 900.66 Million JPY | 199.56% |
| 2010 Q4 | 30.37 Million JPY | -90.0% |
| 2010 FY | 1.4 Billion JPY | -29.89% |
| 2010 Q3 | 303.61 Million JPY | 122.1% |
| 2010 Q2 | 136.7 Million JPY | -84.82% |
| 2009 Q3 | 1.23 Billion JPY | 68295.12% |
| 2009 Q4 | 300.65 Million JPY | -75.63% |
| 2009 FY | 2 Billion JPY | 267.38% |
| 2009 Q2 | 1.8 Million JPY | -99.54% |
| 2009 Q1 | 393.96 Million JPY | 9.89% |
| 2008 Q4 | 358.51 Million JPY | -42.52% |
| 2008 FY | 546.47 Million JPY | 93.81% |
| 2008 Q3 | 623.75 Million JPY | 637.0% |
| 2008 Q2 | -116.15 Million JPY | 0.0% |
| 2007 FY | 281.96 Million JPY | 272.38% |
| 2006 FY | -163.57 Million JPY | -362.5% |
| 2005 FY | -35.36 Million JPY | -107.7% |
| 2004 FY | 459.5 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 95.84 Billion JPY | 92.141% |
| Astellas Pharma Inc. | 124.6 Billion JPY | 93.955% |
| Chugai Pharmaceutical Co., Ltd. | 439.17 Billion JPY | 98.285% |
| Ono Pharmaceutical Co., Ltd. | 163.1 Billion JPY | 95.382% |
| Santen Pharmaceutical Co., Ltd. | 38.54 Billion JPY | 80.457% |
| Daiichi Sankyo Company, Limited | 211.58 Billion JPY | 96.44% |
| Otsuka Holdings Co., Ltd. | 139.61 Billion JPY | 94.605% |
| Perseus Proteomics Inc. | -894.72 Million JPY | 941.819% |